Tarsus Pharmaceuticals (TARS) Capital Expenditures (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Capital Expenditures of $911000.0 for Q1 2026, up 54.41% year-over-year from $590000.0 in Q1 2025, and down 89.1% quarter-over-quarter from $8.4 million in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Capital Expenditures (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $911000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 54.41% year-over-year to $911000.0; the TTM figure through Mar 2026 stood at $10.2 million (up 413.36% YoY), while the FY2025 annual figure was $9.9 million, up 529.16% from the prior year.
- Capital Expenditures for Q1 2026 stood at $911000.0, down from $8.4 million in the prior quarter.
- The five-year high for Capital Expenditures was $8.4 million in Q4 2025, with the low at -$784000.0 in Q4 2023.
- The 5-year median for Capital Expenditures is $257000.0 (2023), against an average of $829375.0.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures sank 660.0% in 2023, then surged 454.01% in 2025.
- Tarsus Pharmaceuticals' Capital Expenditures stood at $140000.0 in 2022, then tumbled by 660.0% to -$784000.0 in 2023, then soared by 292.47% to $1.5 million in 2024, then soared by 454.01% to $8.4 million in 2025, then plunged by 89.1% to $911000.0 in 2026.
- Business Quant data shows TARS's Capital Expenditures at $911000.0 in Q1 2026, $8.4 million in Q4 2025, and -$92000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 4.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.07 Mn |
| Mar 31, 2026 | 5.82 Mn |
| Dec 31, 2025 | 6.36 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 590,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Sep 30, 2024 | 282,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 174,000.00 |
| Sep 30, 2023 | 375,000.00 |
| Jun 30, 2023 | 787,000.00 |
| Mar 31, 2023 | 340,000.00 |
| Dec 31, 2022 | 127,000.00 |
| Sep 30, 2022 | 96,000.00 |
| Jun 30, 2022 | 122,000.00 |
| Mar 31, 2022 | 161,000.00 |
| Dec 31, 2021 | -497,000.00 |
| Sep 30, 2021 | 436,000.00 |
| Jun 30, 2021 | 1.07 Mn |